Abhinav Talwar

Abhinav Talwar

Auto-generated profile, based on publicly available information

Abhinav Talwar

Department of Otolaryngology‐Head and Neck Surgery Northwestern University Feinberg School of Medicine Chicago Illinois USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 March 2023 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
GKGabriel M. Knight
Gabriel M. Knight
AGAndrew C. Gordon
Andrew C. Gordon
VGVanessa Gates
Vanessa Gates
ATAbhinav Talwar
Abhinav Talwar
ARAhsun Riaz
Ahsun Riaz
RLRobert J. Lewandowski
Robert J. Lewandowski

1 December 2021 in Clinical Imaging
Verified
Journal Article
Closed access
ATAbhinav Talwar
Abhinav Talwar
GKGabriel Knight
Gabriel Knight
AAAli Al Asadi
Ali Al Asadi
PEPouya Entezari
Pouya Entezari
RCRichard Chen
Richard Chen
ARAhsun Riaz
Ahsun Riaz

9 August 2022 in Head & Neck
Verified
Journal Article
Closed access
ATAbhinav Talwar
Abhinav Talwar
AGAlex J. Gordon
Alex J. Gordon
ABArnaud F. Bewley
Arnaud F. Bewley
TFTanya Fancy
Tanya Fancy
WLWilliam M. Lydiatt
William M. Lydiatt
BGBabak Givi
Babak Givi

25 July 2023 in The American Surgeon™
Verified
Journal Article
Closed access
ATAbhinav Talwar
Abhinav Talwar
ABAshir Bansal
Ashir Bansal
GKGabriel Knight
Gabriel Knight
JCJuan-Carlos Caicedo
Juan-Carlos Caicedo
ARAhsun Riaz
Ahsun Riaz
RSRiad Salem
Riad Salem
Background: Surgical site drainage is important to prevent hematoma, seroma, and abscess formation. However, the placement of drain placement also predispose patients to several postoperative complications. The aim of this study is to clarify the risk-benefit profile of surgical drain placement. Methods: The American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) Procedure-Targeted Databases were used to identify patients who underwent hepatectomy, pancreatectomy, nephrectomy, cystectomy, and prostatectomy. Patients who underwent each procedure were divided into 2 groups based on intraoperative drain placement. Propensity score-matched cohorts of these 2 groups were compared in terms of postoperative adverse events, readmission, reoperation, and length of stay. Results: Hepatectomy patients with drains experienced organ space infections ( P < .001), sepsis ( P < .001), and readmission ( P = .021) more often than patients without drains. Patients who underwent pancreatectomy and had drains placed experienced wound dehiscence less frequently than those without drains ( P = .04). For hepatectomy, pancreatectomy, nephrectomy, and prostatectomy populations, patients with drains had longer lengths of stay ( P < .05). Matched populations across all procedures did not differ in terms of reoperation rate. Discussion: Prophylactic surgical drain placement may be associated with increased infectious complications and prolonged length of stay. Further studies are needed to elucidate the complete adverse event profile of surgical drains. Nonetheless, outcomes may be improved with better patient selection or advancements in drain technology.

23 August 2022 in Otolaryngology–Head and Neck Surgery
Verified
Journal Article
Closed access
ATAbhinav Talwar
Abhinav Talwar
EPEvan Patel
Evan Patel
MTMoses Tam
Moses Tam
FZFang Zhou
Fang Zhou
KHKenneth Hu
Kenneth Hu
BGBabak Givi
Babak Givi

1 March 2023 in Otolaryngology–Head and Neck Surgery
Verified
Journal Article
Open access
ATAbhinav Talwar
Abhinav Talwar
SKSooyoung Kim
Sooyoung Kim
SYShun Yu
Shun Yu
SSSandeep Samant
Sandeep Samant
YTYesim Tozan
Yesim Tozan
BGBabak Givi
Babak Givi
Objective: To quantify the price that private payers pay hospitals for head and neck squamous cell carcinoma (HNSCC) treatments and identify hospital‐level factors associated with price variation.Study Design: Cross‐sectional study.Setting: Price transparency files.Methods: Files from the top 50 hospitals in otolaryngology according to the US News and World Report were analyzed between December 2021 and June 2022. This study analyzed the following Food and Drug Administration‐approved HNSCC therapies: pembrolizumab, nivolumab, cetuximab, cisplatin, carboplatin, and paclitaxel.Results: Twenty‐four (48%) hospitals reported prices for at least 1 medication in our sample. Newer biologics were significantly more expensive than traditional chemotherapeutic agents. Given approved medication regimens, all biologics in our sample have similar annual costs. Price markups over acquisition costs ranged between 109% (pembrolizumab, nivolumab) and 530% for carboplatin. Across hospitals, prices varied the most for paclitaxel, the cheapest medication in our sample, and prices varied the least for pembrolizumab the most expensive medication in our sample. Hospital 340B status and geographic location in the northeast/west are associated with lower price markups.Conclusion: Price nondisclosure remains a significant problem among hospitals. Newer biological medications are more expensive when compared to traditional chemotherapeutic agents. Prices vary significantly across hospitals, with lower price markups observed in 340B hospitals as well as hospitals located in the geographic northeast and west. It remains to be seen if price transparency will lead to more uniform pricing or lower costs of treatments.